Research programme: nSMASE inhibitors - LpathAlternative Names: neutral sphingomyelinase inhibitors - Lpath
Latest Information Update: 27 Apr 2011
At a glance
- Originator Lpath
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders; Cerebrovascular disorders
Most Recent Events
- 23 Jan 2007 Preclinical trials in Cerebrovascular disorders in USA (unspecified route)
- 23 Jan 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)